Infliximab

About Infliximab

Infliximab, a chimeric monoclonal antibody, is a medication used to treat a number of autoimmune diseases. This includes Crohn's disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriasis, psoriatic arthritis, and Behçet's disease. It is given by slow injection into a vein, typically at six- to eight-week intervals.

Rheumatoid Arthritis

Indicated for reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in patients with moderately-to-severely active rheumatoid arthritis in combination with methotrexate

3 mg/kg IV at 0, 2, and 6 weeks, THEN q8Weeks thereafter  

If incomplete response is noted, dose may be increased to 10 mg/kg OR increasing the dosing frequency to q4Weeks

Psoriatic Arthritis

Indicated for reducing signs and symptoms of active arthritis, inhibiting the progression of structural damage, and improving physical function in patients with psoriatic arthritis

5 mg/kg IV at 0, 2, and 6 weeks, THEN q8Weeks thereafter  

May be used with methotrexate

Plaque Psoriasis

Indicated for the treatment of adult patients with chronic severe (ie, extensive and/or disabling) plaque psoriasis who are candidates for systemic therapy and when other systemic therapies are medically less appropriate

Should only be administered to patients who will be closely monitored and have regular follow-up visits with a physician

5 mg/kg IV at 0, 2, and 6 weeks, THEN q8Weeks thereafter  

Can be used with or without methotrexate

Crohn Disease

IV

• Indicated for moderately-to-severely active Crohn disease in patients who have had inadequate response to conventional therapy
• Also, indicated for reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in adult patients with fistulizing Crohn disease
• 5 mg/kg IV at 0, 2, and 6 weeks, THEN q8Weeks thereafter  
• For adult patients who respond and then lose their response, consideration may be given to treatment with 10 mg/kg
• Patients who do not respond by Week 14 are unlikely to respond with continued dosing and consideration should be given to discontinue

SC

• Indicated for maintenance treatment of moderately to severely active Crohn disease following treatment with an infliximab IV product
• All patients must complete an IV induction regimen (see chosen infliximab product) with an infliximab product before starting SC
• Start at Week 10 or thereafter: 120 mg SC q2Weeks

• Switching from IV to SC maintenance treatment

  • To switch patients who are responding to maintenance therapy with an IV infliximab product, administer first SC dose in place of the next scheduled IV infusion, and then q2Weeks thereafter

Ulcerative Colitis

IV

• Indicated for reducing signs and symptoms, inducing and maintaining clinical remission and mucosal healing, and eliminating corticosteroid use in adults with moderately to severely active ulcerative colitis who have had an inadequate response to conventional therapy
• 5 mg/kg IV at 0, 2, and 6 weeks, then every 8 weeks  

SC

• Indicated for maintenance treatment of moderately to severely active ulcerative colitis following treatment with an infliximab IV product
• All patients must complete an IV induction regimen (see chosen infliximab product) with an infliximab product before starting SC
• Start at Week 10 or thereafter: 120 mg SC q2Weeks

• Switching from IV to SC maintenance treatment

  • To switch patients who are responding to maintenance therapy with an IV infliximab product, administer first SC dose in place of the next scheduled IV infusion, and then q2Weeks thereafter

Ankylosing Spondylitis

Indicated for reducing signs and symptoms in patients with active ankylosing spondylitis

5 mg/kg IV at 0, 2, and 6 weeks, THEN q6Weeks thereafter